首页> 外文期刊>Renal replacement therapy. >Improvement of the fraction of human mercaptalbumin on hemodialysis treatment using hydrogen-dissolved hemodialysis fluid: a prospective observational study
【24h】

Improvement of the fraction of human mercaptalbumin on hemodialysis treatment using hydrogen-dissolved hemodialysis fluid: a prospective observational study

机译:利用氢溶解血液透析液改善血液透析治疗的人巯基霉菌的分数:一种预期观察研究

获取原文
           

摘要

Background Oxidative stress (OS) is said to increase in hemodialysis therapy, so that the electrolyzed water-hemodialysis (EW-HD) dissolving hydrogen in hemodialysis fluid has been tried for the reduction of OS. It is reported that the risk of cardiovascular disease events increased if the fraction of reduced albumin (human mercaptalbumin (f(HMA))) was low and that the f(HMA) rose at the dialyzer outlet on EW-HD. Therefore, we studied whether the f(HMA) of hemodialysis patients was improved when they received long-term EW-HD treatment. Methods We produced hydrogen-dissolved hemodialysis fluid with EW-C81-HD and carried out EW-HD treatment for 12 patients. The serum albumin redox states of pre- and post-HD were measured in the summer of 2014 (EWHD2014) and in the winter of 2015 (EWHD2015) after 6?months by high-performance liquid chromatography using Shodex-Asahipak ES-502N 7C column. For comparison, 38 conventional hemodialysis (C-HD) patients and 24 healthy subjects were selected. Results The f(HMA) of EWHD2015 significantly increased from EWHD2014 on both pre- and post-HD (pre, 51.32?±?5.63?%?→?58.03?±?7.43?%; post, 72.04?±?5.73?%?→?76.42?±?4.67?%). The f(HMA) of C-HD at pre- and post-HD were 51.07?±?9.07 and 70.53?±?8.05?%, respectively. The f(HMA) of healthy subjects was 79.11?±?5.46?%. The f(HMA) of EWHD2014 at pre-HD evidenced no significant difference with that of C-HD at pre-HD, but the f(HMA) of EWHD2015 at pre-HD was significantly higher than that of C-HD at pre-HD. The f(HMA) of C-HD at post-HD was significantly lower than that of both EWHD2015 at post-HD and healthy subjects, but the f(HMA) of EWHD2015 at post-HD showed no significant difference with that of healthy subjects. Conclusions Our data suggest that the f(HMA) may be raised with long-term hemodialysis treatment using hydrogen-dissolved hemodialysis fluid.
机译:背景技术氧化应激(OS)据说增加了血液透析疗法,从而试图减少OS的血液透析液中的电解水 - 血液透析(EW-HD)溶解氢气。据报道,如果减少白蛋白(HMA)(F(HMA))的级分低并且F(HMA)在EW-HD上的透析器出口上升高,则心血管疾病事件的风险增加。因此,我们研究了血液透析患者的F(HMA)在接受长期EW-HD治疗时得到改善。方法采用EW-C81-HD制备氢溶解血液透析液,进行12例患者的EW-HD治疗。在2014年夏季(EWHD2014)和2015年冬季(EWHD2015)的冬季(EWHD2015)冬季通过使用Shodex-Asahipak ES-502N 7C柱进行高效液相色谱(EWHD2014)和2015年冬季(EWHD2015)的血清白蛋白氧化还原状态。相比之下,选择了38例常规血液透析(C-HD)患者和24名健康受试者。结果EWHD2015的F(HMA)从HD和后和后的EWHD214显着增加(PRE,51.32?±5.63?%?→58.03?±→7.43?%;柱,72.04?±?5.73?% ?→76.42?±4.67?%)。在HD和后HD处的C-HDS的F(HMA)分别为51.07Ω·9.07和70.53?±8.05?%。健康受试者的F(HMA)为79.11?±5.46?%。 EWHD2014的F(HMA)在预-HD时明显不具有显着差异,C-HD在HD时的C-HD,但EWHD2015在HD上的F(HMA)显着高于P-HD的C-HD高清。后HD的C-HD的F(HMA)显着低于HD后和健康受试者的EWHD2015的F(HMA),但后HD在后HD的F(HMA)显示出与健康受试者的影响没有显着差异。结论我们的数据表明F(HMA)可以通过使用氢溶解的血液透析液进行长期血液透析处理来提高。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号